Colleen E. Annesley, MD, on Continued Research With T-APCs to Enhance Cell Therapy Persistence

“We're currently examining if it's worth taking T-APCs forward. I think these data are really promising. I think if we get to a point where we can find the right CAR T-cell products going forward, it would have to be a CD19 -targeting CAR product to bring forward CD19 T-APCs. So, we are looking at exploring that in future trials, to see if we could continue to study this and see if, in more patients, we do see that difference and longer-term remissions, longer term persistence of CAR T-cells.”

REFERENCE

Annesley C, Seidel K, Wu QV, et al. A phase 2 trial of SCRI-CAR19 demonstrates favorable leukemia-free survival (LFS), with a pilot study of CD19-expressing T-cell antigen presenting cells (CD19t T-APCs) demonstrating safety and tolerability. Presented at: 2023 ASH Annual Meeting & Exposition, December 9-12; San Diego, California. Abstract 3467